When you start a GLP-1 medication like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro), your prescribing doctor or the medication leaflet may mention pancreatitis as a potential risk. This can feel alarming — especially if you have had stomach trouble before. But what does the evidence actually say, and should you be worried?

Here is a thorough look at what pancreatitis is, what the science shows, and what you should do if warning symptoms appear.

What is pancreatitis?

The pancreas is a gland located behind the stomach that plays two vital roles: it produces digestive enzymes that break down food in the intestine, and it releases the hormones insulin and glucagon that regulate blood sugar.

Pancreatitis is inflammation of the pancreas. There are two main types:

The most common causes of pancreatitis are gallstones and heavy alcohol use. High triglycerides, certain medications, and genetic factors also play a role.

What does the prescribing information say?

The US prescribing information for semaglutide (Ozempic) states that cases of acute pancreatitis, including fatal and non-fatal cases, have been reported during post-marketing use. The label advises that GLP-1 medications should be discontinued if pancreatitis is suspected and not restarted if pancreatitis is confirmed.

The NHS information for semaglutide injection similarly lists severe stomach pain as a symptom that requires urgent medical attention, as it may be a sign of pancreatitis.

This caution is standard practice for a class of medications where a biological signal was observed in early studies — even if the overall risk in large trials has been more reassuring. It is there to protect you, not to alarm you unnecessarily.

What are the warning signs of pancreatitis?

Knowing what to look for is the most important practical step. The classic symptoms of acute pancreatitis include:

It is important to note that mild nausea is a very common and expected side effect of GLP-1 medications — particularly in the early weeks. Mild nausea alone is not a sign of pancreatitis. The hallmark of pancreatitis is severe abdominal pain, especially pain radiating to the back.

What should you do if these symptoms appear?

If you experience severe abdominal pain — with or without nausea, vomiting or fever — while taking a GLP-1 medication:

  1. Stop taking the medication and do not take the next scheduled dose.
  2. Seek medical help immediately — either contact your doctor urgently or go to an emergency department, depending on the severity.
  3. Do not restart the medication until you have spoken to your doctor and pancreatitis has been ruled out or fully resolved.

Pancreatitis is diagnosed with blood tests (elevated pancreatic enzymes) and sometimes imaging. If confirmed, your doctor will decide whether it is safe to continue GLP-1 treatment or whether an alternative approach is needed.

Who is at higher risk?

Certain people may be more vulnerable to pancreatitis in general, and should discuss their history carefully with their doctor before starting a GLP-1 medication:

What does the evidence show?

The scientific picture is more reassuring than the prescribing warnings might initially suggest.

The LEADER trial (Marso et al., 2016, NEJM) was a large cardiovascular outcomes trial involving over 9,000 people with type 2 diabetes taking liraglutide. The rate of acute pancreatitis was 0.4% in the liraglutide group versus 0.5% in the placebo group — a non-significant difference.

The SUSTAIN-6 trial (Marso et al., 2016, NEJM), which studied semaglutide in over 3,000 people, similarly found no statistically significant increase in pancreatitis compared to placebo.

A 2023 meta-analysis (PubMed: 37982580) pooling data from multiple randomised controlled trials found no significant increase in the risk of pancreatitis with GLP-1 receptor agonists overall. The authors noted that while isolated cases have been reported, the absolute risk remains low.

In summary: the biological mechanism raises a question worth monitoring, the prescribing information reflects appropriate caution, and the large trial data is broadly reassuring. The absolute risk of pancreatitis on a GLP-1 medication, for most people, is low.

Should you avoid GLP-1 medications if you have had pancreatitis before?

This is genuinely a question to discuss with your doctor, as guidance varies. Many clinicians and prescribing guidelines advise avoiding GLP-1 medications if you have a history of pancreatitis, particularly if the cause was never fully identified or if you have had recurrent episodes.

However, some doctors may consider GLP-1 treatment even in people with a past episode, especially if the pancreatitis was mild, fully resolved, and a clear and avoidable cause was identified (such as a gallstone that has since been treated). The decision involves weighing the potential benefits — significant improvement in blood sugar, weight and cardiovascular risk — against the uncertainty of risk in an individual who is already predisposed.

If you have a history of pancreatitis and are being considered for a GLP-1 medication, make sure your full medical history is shared with the prescribing clinician before you start.

Keeping the risk in perspective

It is natural to feel unsettled when a medication leaflet lists a serious condition as a possible risk. But context matters. Pancreatitis is listed as a warning because isolated cases have been observed, not because GLP-1 medications are strongly associated with the condition at a population level.

For the vast majority of people taking Wegovy, Ozempic or Mounjaro, pancreatitis will never occur. The clinical trials — which collectively involved tens of thousands of participants — have not found a statistically significant increase in risk compared to placebo. Knowing the warning signs and acting quickly if they appear is the best practical protection you have.

Conclusion

GLP-1 medications carry a label warning about pancreatitis, and it is right to take that seriously. But the large body of clinical evidence, including major cardiovascular outcome trials, has not demonstrated a meaningful increase in risk for most people. The most important things you can do are: be aware of the warning signs, let your doctor know about any relevant risk factors in your history, and seek prompt medical attention if you develop severe abdominal pain.

Always speak to your doctor or pharmacist if you have concerns about pancreatitis and your GLP-1 treatment. Do not stop or change your medication without medical advice.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any decisions about your medication or treatment.

Sources